Mitoxantrone and cyclophosphamide combination chemotherapy for the treatment of various canine malignancies

Henry, CJ; Buss,; Potter, KA; Kj, Wardrop

doi:10.5326/15473317-35-3-236

Cited by 13 publications

(11 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proposed risk factors for SHC in dogs have included high cyclophosphamide dose, prolonged administration, female sex and IV administration . Several papers have also proposed protective factors that may decrease the risk of SHC for dogs taking cyclophosphamide, including the use of diuretics such as prednisone or furosemide and oral cyclophosphamide administration …”

Section: Introductionmentioning

confidence: 66%

“…Multiple studies have indicated that diuretic use with prednisone or furosemide is likely to be protective against development of SHC . In one study, dogs undergoing IV cyclophosphamide for treatment of lymphoma had an SHC prevalence rate of 1.2% with concurrent furosemide treatment versus 9% without .…”

Section: Discussionmentioning

confidence: 99%

“…15 Multiple studies have indicated that diuretic use with prednisone or furosemide is likely to be protective against development of SHC. 2,4,8,11,15,19 In one study, dogs undergoing IV cyclophosphamide for treatment of lymphoma had an SHC prevalence rate of 1.2% with concurrent furosemide treatment versus 9% without. 15 In a study of patients receiving oral cyclophosphamide, the prevalence of SHC when prednisone was given concurrently was 4.8% (8/168 patients) versus 10.5% (7/67 patients) without concurrent prednisone use.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Risk factors for development of sterile haemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case–control study

Gaeta

Brown

Cohen

et al. 2012

Vet Comparative Oncology

View full text Add to dashboard Cite

Sterile haemorrhagic cystitis (SHC) is a known risk of cyclophosphamide treatment; however, most canine reports are case series. This case-control study examined risk factors for SHC in dogs with lymphoma receiving oral cyclophosphamide. Twenty-two dogs with SHC and 66 control dogs were identified. On univariate analysis, SHC risk factors included age (P = 0.041), induction protocol (P = 0.021) and cumulative cyclophosphamide dose (P = 0.002). On multivariate analysis, increasing cumulative cyclophosphamide dose was associated with increased risk of SHC and the 'short' induction protocol (protocol 1) was associated with decreased risk. Controlling for age and induction protocol, odds of SHC increased by 2.21 per 750 mg m(-2) increase in cyclophosphamide dose (P = 0.001). SHC from oral cyclophosphamide is a predominately delayed toxicity resulting from high cumulative doses.

show abstract

Section: Introductionmentioning

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk factors for development of sterile haemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case–control study

Gaeta

Brown

Cohen

et al. 2012

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…Incomplete margins can place the patient at risk for tumour recurrence with reported recurrence rates dependent on grade: 7% for grade 1, 34% for grade 2 and 75% for grade 3. 1,3 Findings of incomplete excision can lead to recommendations for further treatment including chemotherapy, [3][4][5][6][7][8][9][10][11][12][13] radiation therapy [11][12][13][14][15][16][17][18] or further surgery 3,[11][12][13][14][18][19][20] to decrease chance of recurrence or increase time to recurrence.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of information presented within soft tissue sarcoma histopathology reports in the United States: 2012‐2015

Livaccari

Selmic

Reagan

et al. 2018

Vet Comparative Oncology

View full text Add to dashboard Cite

Despite the existence of the American College of Veterinary Pathology guidelines for tumour biopsy specimens, anecdotally the authors' have seen inconsistency of reporting of information on the pathology report for canine soft tissue sarcomas (STSs). If crucial aspects are not reported this can result in slower or impeded patient care. This retrospective study evaluated 255 STS histopathology reports submitted from across the United States. Reports were evaluated by a single observer to assess for information contained in 5 main categories: patient history and signalment, gross and microscopic description, grading, histologic margins and the comments section. Inclusion criteria for histopathology reports included a final diagnosis of STS, having a microscopic description and resulting from the initial surgical resection. The majority of the reports stated the patient signalment (91.2%) and clinical history (90.8%). However, only 64.8% of the reports had a gross description of the specimen. Histologic margin description was present in 229 reports (91.6%), however, only 149 reports (59.6%) stated an objective measurement of these margins. Histologic classification was stated in 50.0% of the reports, while grade was given on 97.2% of the reports. Variability in histopathologic reporting including histologic margin description for resected canine STS was identified. Given surgical treatment is the mainstay for STS and histopathological assessment plays an important role in determination of whether additional surgery, radiation or chemotherapy is needed. Standardization or checklists like the American College of Pathology utilize may be helpful to ensure histopathologic characteristics are reported that may guide further treatment recommendations.

show abstract

“…Current treatment recommendations are local control with curative-intent surgery and/or radiation therapy and systemic adjunctive therapy [ 20 ]. The median survival time (MST) in canine oral malignant melanoma is significantly shorter for tumors at more advanced stages in the World Health Organization (WHO) clinical staging system [ 3 , 10 , 12 ]. Thus, early detection is desirable, but is also difficult, because there are few opportunities to check the inside of the mouth.…”

mentioning

confidence: 99%

Profiling of plasma metabolites in canine oral melanoma using gas chromatography-mass spectrometry

Kawabe

Baba

Tamai

et al. 2015

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

Malignant melanoma is one of the most common and aggressive tumors in the oral cavity of dog. The tumor has a poor prognosis, and methods for diagnosis and prediction of prognosis after treatment are required. Here, we examined metabolite profiling using gas chromatography-mass spectrometry (GC-MS) for development of a discriminant model for evaluation of prognosis. Metabolite profiles were evaluated in healthy and melanoma plasma samples using orthogonal projection to latent structure using discriminant analysis (OPLS-DA). Cases that were predicted to be healthy using the OPLS discriminant model had no advanced lesions after radiation therapy. These results indicate that metabolite profiling may be useful in diagnosis and prediction of prognosis of canine malignant melanoma.

show abstract

Mitoxantrone and cyclophosphamide combination chemotherapy for the treatment of various canine malignancies

Cited by 13 publications

References 3 publications

Risk factors for development of sterile haemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case–control study

Risk factors for development of sterile haemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case–control study

Evaluation of information presented within soft tissue sarcoma histopathology reports in the United States: 2012‐2015

Profiling of plasma metabolites in canine oral melanoma using gas chromatography-mass spectrometry

Contact Info

Product

Resources

About